Glycolytic inhibition with 3-bromopyruvate suppresses tumor growth and improves survival in a murine model of anaplastic thyroid cancer

Surgery ◽  
2021 ◽  
Author(s):  
Bixiao Zhao ◽  
Abha Aggarwal ◽  
Jessica A. Marshall ◽  
Justine A. Barletta ◽  
Marie F. Kijewski ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Tumor Growth ◽  
Murine Model ◽  
Anaplastic Thyroid Cancer

scholarly journals Targeted Therapy of VEGFR2 and EGFR Significantly Inhibits Growth of Anaplastic Thyroid Cancer in an Orthotopic Murine Model

2011 ◽  
Vol 17 (8) ◽  
pp. 2281-2291 ◽  
Author(s):  
Maria K. Gule ◽  
Yunyun Chen ◽  
Daisuke Sano ◽  
Mitchell J. Frederick ◽  
Ge Zhou ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Targeted Therapy ◽  
Murine Model ◽  
Anaplastic Thyroid Cancer

scholarly journals Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer

Oncotarget ◽  
2015 ◽  
Vol 6 (11) ◽  
pp. 9073-9085 ◽  
Author(s):  
Lisa Zhang ◽  
Yaqin Zhang ◽  
Amit Mehta ◽  
Myriem Boufraqech ◽  
Sean Davis ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Tumor Growth ◽  
Anaplastic Thyroid Cancer ◽  
Egfr Signaling ◽  
Dual Inhibition ◽  
Tumor Growth And Metastasis

scholarly journals Combined BRAFV600E- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer

Oncotarget ◽  
2014 ◽  
Vol 5 (12) ◽  
pp. 3996-4010 ◽  
Author(s):  
Pierre Vanden Borre ◽  
Viswanath Gunda ◽  
David G. McFadden ◽  
Peter M. Sadow ◽  
Shohreh Varmeh ◽  
...  
Keyword(s):  
Immune Response ◽  
Thyroid Cancer ◽  
Mouse Model ◽  
Tumor Growth ◽  
Anaplastic Thyroid Cancer ◽  
Orthotopic Mouse Model

Efficacy of adavosertib therapy against anaplastic thyroid cancer

2021 ◽  
Author(s):  
Yu-Ling Lu ◽  
Yu-Tung Huang ◽  
Ming-Hsien Wu ◽  
Ting-Chao Chou ◽  
Richard J Wong ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Tumor Growth ◽  
Single Agent ◽  
Xenograft Model ◽  
Anaplastic Thyroid Cancer ◽  
Therapeutic Effects ◽  
Dependent Manner ◽  
Cancer Tumor

Wee1 is a kinase that regulates the G2/M progression by inhibition of CDK1, which is critical for ensuring DNA damage repair before initiation of mitotic entry. Targeting Wee1 may be a potential strategy in the treatment of anaplastic thyroid cancer, a rare but lethal disease. The therapeutic effects of adavosertib, a Wee1 inhibitor for anaplastic thyroid cancer was evaluated in this study. Adavosertib inhibited cell growth in three anaplastic thyroid cancer cell lines in a dose-dependent manner. Cell cycle analysis revealed cells were accumulated in the G2/M phase. Adavosertib induced caspase-3 activity and led to apoptosis. Adavosertib monotherapy showed significant retardation of the growth of two anaplastic thyroid cancer tumor models. The combination of adavosertib with dabrafenib and trametinib revealed strong synergism in vitro and demonstrated robust suppression of tumor growth in vivo in anaplastic thyroid cancer xenograft models with BRAFV600E mutation. The combination of adavosertib with either sorafenib or lenvatinib also demonstrated synergism in vitro and had strong inhibition of tumor growth in vivo in an anaplastic thyroid cancer xenograft model. No appreciable toxicity appeared in mice treated with either single agent or combination treatment. Our findings suggest adavosertib holds the promise for the treatment of patients with anaplastic thyroid cancer.

scholarly journals Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer

Oncotarget ◽  
2016 ◽  
Vol 7 (13) ◽  
pp. 17194-17211 ◽  
Author(s):  
Eran Brauner ◽  
Viswanath Gunda ◽  
Pierre Vanden Borre ◽  
David Zurakowski ◽  
Yon Seon Kim ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Tumor Immunity ◽  
Murine Model ◽  
Tumor Regression ◽  
Braf Inhibitor ◽  
Anaplastic Thyroid Cancer

scholarly journals Theranostic near-infrared fluorescent nanoplatform for imaging and systemic siRNA delivery to metastatic anaplastic thyroid cancer

2016 ◽  
Vol 113 (28) ◽  
pp. 7750-7755 ◽  
Author(s):  
Yanlan Liu ◽  
Viswanath Gunda ◽  
Xi Zhu ◽  
Xiaoding Xu ◽  
Jun Wu ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Tumor Growth ◽  
Solid Tumors ◽  
Target Genes ◽  
Near Infrared ◽  
Clinical Success ◽  
Sirna Delivery ◽  
Anaplastic Thyroid Cancer ◽  
Nir Imaging ◽  
Tumor Accumulation

Anaplastic thyroid cancer (ATC), one of the most aggressive solid tumors, is characterized by rapid tumor growth and severe metastasis to other organs. Owing to the lack of effective treatment options, ATC has a mortality rate of ∼100% and median survival of less than 5 months. RNAi nanotechnology represents a promising strategy for cancer therapy through nanoparticle (NP) -mediated delivery of RNAi agents (e.g., siRNA) to solid tumors for specific silencing of target genes driving growth and/or metastasis. Nevertheless, the clinical success of RNAi cancer nanotherapies remains elusive in large part because of the suboptimal systemic siRNA NP delivery to tumors and the fact that tumor heterogeneity produces variable NP accumulation and thus, therapeutic response. To address these challenges, we here present an innovative theranostic NP platform composed of a near-infrared (NIR) fluorescent polymer for effective in vivo siRNA delivery to ATC tumors and simultaneous tracking of the tumor accumulation by noninvasive NIR imaging. The NIR polymeric NPs are small (∼50 nm), show long blood circulation and high tumor accumulation, and facilitate tumor imaging. Systemic siRNA delivery using these NPs efficiently silences the expression of V-Raf murine sarcoma viral oncogene homolog B (BRAF) in tumor tissues and significantly suppresses tumor growth and metastasis in an orthotopic mouse model of ATC. These results suggest that this theranostic NP system could become an effective tool for NIR imaging-guided siRNA delivery for personalized treatment of advanced malignancies.

Dual effects for lovastatin in anaplastic thyroid cancer: the pivotal effect of transketolase (TKT) on lovastatin and tumor proliferation

2018 ◽  
Vol 66 (5) ◽  
pp. 1.4-9 ◽  
Author(s):  
Chih-Yuan Wang ◽  
Hao-Ai Shui ◽  
Tien-Chun Chang
Keyword(s):  
Thyroid Cancer ◽  
Cell Growth ◽  
Protein Expression ◽  
Tumor Growth ◽  
Anaplastic Thyroid Cancer ◽  
Control Group ◽  
Cancer Cell Growth ◽  
Protein Levels

This study tested the hypothesis that the effects of lovastatin on anaplastic thyroid cancer cell growth are mediated by upregulation of transketolase (TKT) expression. The effects of lovastatin on TKT protein levels in ARO cells were determined using western blot and proteomic analyses. After treatment with lovastatin and oxythiamine, the in vitro and in vivo growth of ARO cells was determined using 3-(4,5-Dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) assays and tumor xenografts in nude mice. TKT protein expression in the ARO tumors was assessed using immunohistochemistry analysis. Proteomic analysis revealed that 25 µM lovastatin upregulated TKT expression. Co-treatment of ARO cells with 1 µM lovastatin + 1 µM oxythiamine increased TKT protein expression compared with control levels; however, no differences were observed with 10 µM lovastatin + 1 µM oxythiamine. Furthermore, treatment with either oxythiamine or lovastatin alone reduced ARO tumor expression of TKT, as well as decreased ARO cell proliferation in vitro and tumor growth in vivo. However, mice treated with both lovastatin and oxythiamine at the same time had tumor volumes similar to that of the untreated control group. We conclude that either lovastatin or oxythiamine reduced ARO cell growth; however, the combination of these drugs resulted in antagonism of ARO tumor growth.

Sign in / Sign up

Export Citation Format

Share Document